Characterization of binding specificity using GST-conjugated mutant huntingtin epitopes in surface plasmon resonance (SPR) |
Cho, Hang-Hee
(Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
Kim, Tae Hoon (Department of Food Science and Biotechnology, Daegu University) Kim, Hong-Duck (Department of Public Health (Division of Environmental Health Science), New York Medical College) Cho, Jae-Hyeon (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) |
1 | Hackam AS, Singaraja R, Zhang T, Gan, L. Hayden MR. 1999. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Hum Mol Genet. 8: 25-33. DOI |
2 | Jana NR, Tanaka M, Wang G, Nukina N. 2000. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity, Hum Mol Genet. 9: 2009-18. DOI |
3 | Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, Kalchman M, Hayden MR. 1998. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol. 141: 1097-105. DOI |
4 | Kim S, Nollen EA, Kitagawa K, Bindokas VP, Morimoto RI. 2002. Polyglutamine protein aggregates are dynamic. Nat Cell Biol. 4: 826-31. DOI |
5 | Li SH, Li XJ. 1998. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum Mol Genet. 7: 777-82. DOI |
6 | Marquette A, Aisenbrey C, Bechinger B. 2021. Membrane Interactions Accelerate the Self-Aggregation of Huntingtin Exon 1 Fragments in a Polyglutamine Length-Dependent Manner. Int J Mol Sci. 22(13): 6725. DOI |
7 | Lunkes A, Trottier Y, Fagart J, Schultz P, Zeder-Lutz G, Moras D, Mandel JL. 1999. Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease. Philos Trans R Soc Lond B Biol Sci. 354: 1013-1019. DOI |
8 | Koshy BT, Zoghbi HY. 1997. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Brain Pathol. 7: 927-42. DOI |
9 | Li SH, Cheng AL, Zhou H, Lam S, Rao M, Li H, Li XJ. 2002. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol Cell Biol. 22: 1277-87. DOI |
10 | Li SH, Li XJ. 2004. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends in Genetics. 20: 146-154. DOI |
11 | Martin JB, Gusella J. 1986. Huntington's disease. Pathogenesis and management. N Engl J Med. 315; 1267-76. DOI |
12 | Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja RKazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR. 1998. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet. 18: 150-4. DOI |
13 | Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattane E. 2003. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 35: 76-83. DOI |
14 | Narain Y, Wyttenbach A, Rankin J, Furlong RA, Rubinsztein DC. 1999. A molecular investigation of true dominance in Huntington's disease. J Med Genet. 36: 739-46. DOI |
15 | Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E. 2000. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci. 20: 3705-13. DOI |
16 | Moulder KL, Onodera O, Burke JR, Strittmatter WJ, Jr. Johnson EM. 1999. Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length. J Neurosci. 19: 705-15. DOI |
17 | Yang H, Yang S, Jing L, Huang L, Chen L, Zhao X, Yang W, Pan Y, Yin P, Qin ZS, Tang B, Li S, Li XJ. 2020. Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is akey pathogenic form. Nat Commun. 11(1): 2582. DOI |
18 | Reddy PH, Williams M, Tagle DA. 1999. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 22: 248-55. DOI |
19 | Sharp AH, Love SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA. Steiner JP, Lo A, Hedreen J, Sisodia S, Snyder SH, Dawson TM, Ryugo DK, Ross CA. 1995. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14: 1065-74. DOI |
20 | World Health Organization. 2019.disorders. https://www.who.int/news-room/fact-sheets/detail/mental-disorders. |
21 | Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Crauford D, Curtis A, Curtis D, Davidson MJ, Differ AM, Dode C, Dodge A, Frontali M, Ranen NG, Stine OC, Sherr M, Abbott MH, Franz ML, Graham CA, Harper PS, Hedreen JC, Jackson A, Kaplan JC, Losekoot M, MacMillan JC, Morrison P, Trottier Y, Novelletto A, Simpson SA, Theilmann J, Whittaker JL, Folstein SE, Ross CA, Hayden MR. 1996. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet. 59: 16-22. |
22 | Preisinger E, Jordan BM, Kazantsev A, Housman D. 1999. Evidence for a recruitment and sequestration mechanism in Huntington's disease. Philos Trans R Soc Lond B Biol Sci. 354: 1029-34. DOI |
23 | Bano D, Zanetti F, Mende Y, Nicotera P. 2011. Neurodegenerative processes in Huntington's disease. Cell Death Dis. 10;2(11): e228. DOI |
24 | Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, Kim J, Young AB, Penney J, Golden J, Aronin N, M. DiFiglia M. 1996. Expression of normal and mutant huntingtin in the developing brain. J Neurosci. 16: 5523-35. DOI |
25 | Burrus CJ, McKinstry SU, Kim N, Ilcim Ozlu M, Santoki AV, Fang FY, Ma A, Karadeniz YB, Worthington AK, Dragatsis I, Zeitlin S, Yin HH, Eroglu C. 2020. Striatal Projection Neurons Require Huntingtin for Synaptic Connectivity and Survival. Cell Rep. 30(3): 642-657. DOI |
26 | Busch A, Engemann S, Lurz R, Okazawa H, Lehrach H, Wanker EE. 2003. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease. J Biol Chem. 278: 41452-61. DOI |
27 | Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Masone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, Ross CA. 1998. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet. 7: 783-90. DOI |
28 | Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson Jr EP. 1985. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 44; 559-77. DOI |
29 | DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277: 1990-3. DOI |
30 | Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D. 2002. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 296: 2238-43. DOI |
31 | Walker FO, 2007. Huntington's disease. Lancet. 369 (9557): 218-28. DOI |
32 | Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M. 2018. Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases. Front Neurosci. 12: 75. DOI |